Kornimate/medical-research-clean huggingface dataset:
efficacy of kovir capsule in the combination regimen with background treatment in covid-19 patients

Conditions: COVID-19

Summary: the acute pneumonia pandemic caused by a new strain of corona virus 2019, namely as covid-19 by the world health organization (who), is a pandemic caused by sars-cov-2 virus. the reported symptoms vary from fever or chills, cough, shortness of breath, to muscle aches, headaches, loss of taste or smell. the capsule kovir is a product based on the traditional medicine named "ren shen bai du san" which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine.

the acute pneumonia pandemic caused by a new strain of corona virus 2019, namely as covid-19 by the world health organization (who), is a pandemic caused by sars-cov-2 virus. the reported symptoms have included, but are not limited to fever or chills, cough, shortness of breath, muscle aches, headaches, loss of taste or smell, diarrhea, dizziness, sore throat, abdominal pain, anorexia, and vomiting. the capsule kovir is a product based on the traditional prescription named "ren shen bai du san" which is used to treat the cold conditions, also known as the initial plague according to the theory of traditional medicine. the study compares between standard dose regimen of kovir combined with background treatment in covid-19 patients and only background treatment in covid-19 patients. the study will enroll 700 participants to kovir group and 300 participant to non-kovir group. all participants will be treated and followed up in 14-day period. in case the participant meets the discharge criteria before 14 days, discontinuing the study drug will be done at the discretion of the investigators. screening procedures occur at day 1. periodic assessments are conducted daily from day 2-14. finally, end of study visit is conducted.

Eligibility criteria:
inclusion criteria: * male or female, aged from 18-65, vietnamese nationality * participants diagnosed with positive result of sars-cov-2 using real time rt-pcr test, ct value \ 3log) * voluntary participation in the study by signing an informed consent * ability to adhere to treatment according to the investigator's assessment exclusion criteria: * symptoms of severe upper and lower respiratory tract infections such as dyspnea, spo2\<93%. * acute reduction of ventilation function of respiratory apparatus and/or respiration function of the lung in any of the following three groups: * respiratory distress due to hypoxemia with pao2 less than 60mmhg when breathing room air. * respiratory distress due to hypercapnia with paco2 above 50mmhg * mixed respiratory distress accompanied by both a decrease in pao2 and an increase in paco2 * allergy/intolerance to any component of the study drug. * inability to administer medicine. * severe pneumonia as assessed by the investigator. * inability to comply with study procedures or to ensure compliance with study drug administration as assessed by investigators.
using soy estrogens to prevent bone loss and other menopausal symptoms

Conditions: Menopause; Osteoporosis; Osteopenia

Summary: the purpose of this study is to determine if soy-derived phytoestrogens (naturally occurring compounds similar to estrogen) can prevent bone loss and other menopausal symptoms in women who have recently gone through menopause. study hypothesis: tablets of high-dose, purified soy phytoestrogens spare the normally occurring spinal bone loss and improve biological and other emotional changes of menopause.

the risks of bone loss and osteoporosis increase significantly after menopause. although hormone therapy (ht) can spare menopausal women from bone loss and other menopausal symptoms, women's health initiative (whi) findings indicate significant potential health risks associated with ht. this has prompted women to switch from ht to naturally occurring compounds similar to estrogen, such as those derived from soy, in the hope that estrogens from plant sources can provide benefits while sparing adverse effects caused by prescribed estrogens. however, the long-term efficacy and safety of plant estrogens are unknown. this study will evaluate the effectiveness of treatment using purified soy isoflavones, a dietary source of phytoestrogens, in preventing bone loss, menopausal symptoms, and other changes associated with estrogen deficiency in young menopausal women. the "soy phytoestrogens as replacement estrogen (spare)" study will provide a foundation of knowledge from which menopausal women and their doctors can begin to make more informed decisions regarding ht and other treatment options. enrollment into the study will occur over 3 years, with each participant taking part in the study for a total of 2 years. participants will be randomly assigned to one of two groups; the first group will receive a 200 mg dose of soy isoflavones daily and the second group will receive placebo daily. there will be 10 study visits: screening, study entry, randomization at month 1, six follow-up visits at months 2, 4, 8, 12, 16, 20, and a final visit at the end of active participation at month 24. at each study visit, participants will have blood drawn, provide urine samples, answer questionnaires, and have mammograms and bone density tests.

Eligibility criteria:
inclusion criteria * absence of menstrual period for 12 months but not more than 5 years, or absence of menstrual period for 6 to 12 months and follicle stimulating factor (fsh) greater than 40 iu/l exclusion criteria * treatment with estrogens, progesterone, raloxifene, or tamoxifen * treatment with bisphosphonates, calcitonin, fluoride, or systemic corticosteroids * use of soy/herbal supplements, including dhea, within 3 months prior to study entry * use of antibiotics in the month prior to study entry * use of prescription medication to treat hot flashes * chemical menopause, including post-chemotherapy * hyperthyroidism * hypothyroidism * uncontrolled diabetes * malabsorption syndromes or other chronic diseases * body mass index (bmi) less than 20 or greater than 32 * bone mineral density (bmd) t-score below -2.0 in lumbar spine or femoral neck
proposal of a novel model for identifying complete response in dmmr colon cancer following neoadjuvant immunotherapy

Conditions: Colorectal Cancer

Summary: in this study, we developed a novel evaluation model for identifying complete response following neoadjuvant immune checkpoint inhibitor therapy therapy in patients with dmmr colon cancer, validated its efficacy in two independent cohorts, and assessed its feasibility for w\&w strategy.

immunotherapy shows promise as a curative treatment for patients with non-metastatic dmmr crc, and offers an option of watch-and-wait (w\&w) strategy for those achieving clinical complete response (ccr). a recent study by cercek et al. has tested this hypothesis and demonstrated that 100% of patients (n=42) with localized dmmr rectal cancer achieved ccr after 6 months of neoici treatment. these patients were managed with a w\&w strategy, and none experienced tumor recurrence over a median follow-up of 26.3 (range 12.4-50.5) months. this result was echoed by our previous studies, in which patients with dmmr rectal cancer who achieved ccr following neoici demonstrated promising long-term outcomes. organ preservation seems promising not only in patients with dmmr rectal cancer, but also in those with dmmr colon cancer who achieve ccr. in the neocap trail, 20 patients with colon cancer were managed with a w\&w strategy, with no tumour regrowth observed over a median follow-up of 11.2 (iqr 5.1-17.7) months. however, the application of organ preservation remains a significant challenge in dmmr colon cancers. this is largely attributed to the fact that tumor responses to neoici are more prone to be underestimated by radiological assessment. specifically, patients with pcr were often evaluated as having residual diseases on ct scans. in the picc trail, 80% (24/30) of patients with partial response (pr) were found to achieve pcr after tumor resection. similarly, in the niche-2 study, only 2 out of 75 patients with pcr had a radiological complete response (cr).5 hence, a more reliable evaluation model to identify pcr after neoici in dmmr colon cancer is urgently needed. in the present study, we developed a novel evaluation model for identifying cr following neoici therapy in patients with dmmr colon cancer, validated its efficacy in two independent cohorts, and assessed its feasibility for w\&w strategy.

Eligibility criteria:
inclusion criteria: 1. pathologically confirmed colon adenocarcinoma; 2. immunohistochemistry testing as dmmr tumors; 3. received at least two doses of anti-pd-1 immunotherapy in a neoadjuvant setting. 4. received radical surgery. exclusion criteria: -
clinical application of near-infrared whole body heat shock multimodal technique in treatment of castration-resistant prostate cancer

Conditions: Metastatic Castration-resistant Prostate Cancer (CRPC)

Summary: in this study, we propose to use the combination of et-space nir irradiation whole-body thermal stimulation, ici (tislelizumab), and rtk inhibitor (anlotinib) in the multimodal treatment of crpc.

the initial efficacy and safety of the multimodal therapy will be evaluated at the animal level to fully validate the potential feasibility of the therapy. subsequently, the efficacy of the multimodal therapy will be verified at the organoid level, and based on which a translational randomized controlled clinical trial will be conducted to evaluate the efficacy and safety of the multimodal therapy at the human level, and the patients will be followed up for a long period of time, so as to collect detailed data on improvement of the quality of life. finally, the synergistic effect of the multimodal therapy will be analyzed at the molecular and cellular levels.

Eligibility criteria:
inclusion criteria: * histopathologically confirmed diagnosis of pc and clinically confirmed diagnosis of crpc; * complete and reliable medical history and medical records; * no other primary tumors except crpc; * blood tests, liver function, renal function and electrocardiogram are basically normal; * patients with ecog score 0\~3, aged ≥18 years and \<90 years old; * patients with good compliance, able to accept regular follow-up. exclusion criteria: * history of malignant tumor other than pc within the past 5 years; * severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study; * accompanied by severe underlying diseases that cannot tolerate this therapy; * with acute diseases, such as acute infection, active bleeding; * those who have recently participated in other clinical trials and have not passed the washout period; * those who cannot tolerate systemic heat stress, such as claustrophobic patients; * those who have a history of allergy to the drugs used in the trial; * patients with other reasons for not being able to be enrolled in the study, according to the study doctor.

Keywords: hyperthermia, immune checkpoint inhibitor, rtk inhibitor, crpc
effect of metformin versus repaglinide treatment in non-obese type 2 diabetic patients uncontrolled by diet

Conditions: Diabetes Mellitus, Type 2

Summary: background: metformin is the first drug of choice in obese patients with type-2 diabetes (t2dm) due to its antiglycaemic as well as its cardiovascular protective potentials. in non-obese t2dm patients insulin-secretagogues are empirically used as first choice. the aim of this study was to evaluate the effect of metformin versus an insulin-secretagogue, repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in non-obese patients with t2dm. methods: single-center, randomised, double-masked, double-dummy, cross-over-study of 96 non-obese (bmi ≤ 27 kg/m2) caucasian t2dm-patients. after a one month run-in on diet-only treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d). followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months with a one month wash-out between interventions.


Eligibility criteria:
inclusion criteria: type-2 diabetes, defined as: * age at onset of diabetes ≥ 40 years * fasting serum c-peptide ≥ 300 pmol/l or a non-fasting or glucagon-stimulated serum c-peptide ≥ 600 pmol/l * no history of ketonuria or ketoacidosis. * bmi ≤ 27 kg/m2. * fasting plasma-glucose ≥ 6.5 mmol/l after at least one month of diet-only treatment. * hba1c ≤ 9.5% at ongoing oral anti-hyperglycaemic agents. hba1c ≥ 6.5% after minimum one month of diet-only treatment. * weight-loss of no more than 5.0 kg during the last 6 months prior to enrolment. exclusion criteria: * type-1 diabetes * insulin-treated type-2 diabetes * secondary diabetes, heart-failure * serum-creatinine above the upper limit * serum-asat elevated more than 3 fold above the upper limit * factor ii-vii-x decreased below 0.7 * ongoing coexisting illnesses with a life-shortening prognosis * mental retardation or reduced intellectual behaviour * pregnancy * history of drug-abuse or hba1c\>10.5% at two separate visits with at least one month interval during treatment-periods.
cardiometry versus fluid and catheter treatment trial (factt lite) on fluid management in acute respiratory distress syndrome patients

Conditions: ARDS; Fluid Management; Cardiometry

Summary: the aim of this study will be to compare the fluid management in acute respiratory distress syndrome ards guided by electrical cardiometry (ec) versus the guidance with simplified conservative fluid protocol, fluid and catheter treatment trial "factt lite". group (a) consists of 35 patients: fluid management in this group will follow a simplified conservative fluid protocol, "factt lite" the factt lite provided three possible instructions determined by the cvp and urine output: furosemide administration, fluid bolus, or no intervention. group (b) consists of 35 patients: fluid will be allowed according to an ftc-based fluids algorithm protocol and the type of bolus fluids will be determined according to transthoracic fluid content (tfc), vasopressors and inotropes will be given according to reading of ec reading of systemic vascular resistance (svr) and index of contractility (i con).


Eligibility criteria:
inclusion criteria: * acute onset within one week * mild to moderate ards (fio2/pao2) less than 300 mmhg and more than 100 mmhg with a minimum peep of 5 cmh2o * bilateral lung opacities consistent with pulmonary edema on chest radiogram or lung ultrasound, cardiac failure, and fluid overload should be excluded in the absence of a definite cause of ards * ards due to pulmonary cause. exclusion criteria: * hemodynamic instability, patients on vasopressor, * barotrauma * organ/s dysfunction at presentation. * pregnant
effects of intramural fibroids on ivf outcome

Conditions: Infertility, Female; Assisted Reproduction

Summary: a cohort study involving 200 women candidate for ivf / icsi cycles . the participants will be assessed through full history-taking with special consideration to age and the duration, type, and cause of infertility. the medical examination included general, abdominal, and vaginal examinations. finally, an ultrasonography examination was performed to check for the presence of three or more preantral follicles and to exclude ovarian cysts. on day 3 of a natural cycle, a baseline levels of fsh, luteinizing hormone (lh), , estradiol and anti-müllerian hormone (amh).ovarian stimulation was performed using a long, antagonist, or short protocol. they were assigned to one of the 2 groups according to having an intramural myoma not indenting the cavity or not. all will be followed up by transvaginal ultrasonography . when two or more follicles had reached a mean diameter of 18 mm, oocyte maturation was triggered by intramuscular administration of hcg. embryo transfer will be done at day 2, 3 or 5 according to the circumstances.

a cohort study involving 200 women candidate for ivf / icsi cycles . the participants will be assessed through full history-taking with special consideration to age and the duration, type, and cause of infertility. the medical examination included general, abdominal, and vaginal examinations. finally, an ultrasonography examination was performed to check for the presence of three or more preantral follicles and to exclude ovarian cysts. on day 3 of a natural cycle, a baseline levels of fsh, luteinizing hormone (lh), , estradiol and anti-müllerian hormone (amh).ovarian stimulation was performed using a long, antagonist, or short protocol. they were assigned to one of the 2 groups according to having an intramural myoma not indenting the cavity or not. all will be followed up by transvaginal ultrasonography . when two or more follicles had reached a mean diameter of 18 mm, oocyte maturation was triggered by intramuscular administration of hcg. embryo transfer will be done at day 2, 3 or 5 according to the circumstances.

Eligibility criteria:
inclusion criteria: * age younger than 40 years * fsh) less than 10 iu/l * serum prolactin level normal * uterine cavity abnormality was excluded by hysteroscopy or hysterosalpingography. exclusion criteria: * abnormal endocrine function (e.g. abnormal thyroid or adrenal function) * ovarian cysts, * hydrosalpinx * endometrial polyps * male partner with azoospermia * icsi performed for preimplantation genetic diagnosis.
design and implementation of a nutritional intervention in patients with oropharyngeal dysphagia

Conditions: Oropharyngeal Dysphagia

Summary: the purpose of this trial is to design, implement and evaluate the effect of a nutritional intervention in patients with oropharyngeal dysphagia on body composition and oral intake of energy and protein.

oropharyngeal dysphagia causes complications that compromise the efficacy and security of deglutition. an inefficacy deglutition increases the risk of malnutrition and/or dehydration. on the other hand, unsafe deglutition requires more time to complete the oral preparation of the bolus, which can leave residues in the mouth that can then lead to penetration of small food particles into the respiratory tract. these tracheobronchial aspirations cause aspiration pneumonia in 50% of cases, with 50% of mortality rate. despite the enormous impact of oropharyngeal dysphagia in functional capacity and quality of life, this problem is underestimated and underdiagnosed as a major cause of nutritional and pulmonary complications that generate more material and human resources. there are few studies evaluating the effect of a nutritional intervention on recovery in swallowing ability or improvement of nutritional status. the purpose of this trial is to design a nutritional intervention with modified texture foods to increase viscosity (measured accurately) according to the patient's requirements, also assess if the intervention has a positive effect on the swallowing ability, calorie and protein oral intake and nutritional status.

Eligibility criteria:
inclusion criteria: * diagnosis of oropharyngeal dysphagia. * patients who have primary caregiver. * agreeing to participate in the study. exclusion criteria: * critically ill patients. * chronic kidney disease with glomerular filtration rate \<30 ml / min or in renal replacement therapy * liver failure. * cancer with active radiotherapy or chemotherapy treatment. * patients who are participating in another study.

Keywords: nutritional intervention in oropharyngeal dysphagia
effective methods of reducing lower back, neck and shoulder pain among office workers

Conditions: Musculoskeletal Pain; Low Back Pain

Summary: background:musculoskeletal discomforts (msd), especially in the neck, lower back and shoulder areas, are some of the most common issues among office workers. the social security organization (socso) in malaysia caps number of cases involving musculoskeletal injuries at a maximum of 10,000 per year. objectives: the primary aims of this research were to: 1. measure the prevalence of msd in a sample of office workers; 2. test effective methods of reducing lower back, neck and shoulder pain in this sample by training exercise, or ergonomics modification, or both of them; and 3. assess discomfort scores and the range of motion of the lower back, neck and shoulder muscles among the office workers after undertaking the different methods for a period of 6 months. methods: in a true experimental design, from 10,000 staff in telecom malaysia,onehundred and forty two office workers (of whom 50 were male), aged 20-50 y, were allocated randomly, from 3 different locations (bangsar, puchung, and damansara), to one of three intervention groups (receiving training exercise, receiving modified ergonomics, receiving a combination of exercise and ergonomics modification) and a control group (receiving none of these interventions). the cornell msd questionnaire was used to measure musculoskeletal discomforts, with focus on pain severity, before treatment and after 2, 4 and 6 months of the interventions. the range of motion (rom) of the hip, neck, shoulder and knee were measured by a 12 inch goniometer, and the borg cr10 scale was used to measure the perceived exertion of training exercises. the rapid office strain assessment (rosa) questionnaire was used to assess the strain associated with office work. height and weight were also measured to calculate the body mass index (bmi).

it is expected that, 6 months intervention including exercise training, ergonomic modification and mixture of these 2 intervention, maybe can decrease the severity of pain in lower back, neck and shoulder among office workers.

Eligibility criteria:
inclusion criteria: * working in office exclusion criteria: * any physical or mental disease any surgery in background any limitation by dr

Keywords: exercise